South Korea Approves Two New Drugs in April, Hits Record Pace

South Korean researchers are turning out life-saving medications at a pace that would have seemed impossible just a few years ago.

The country approved two groundbreaking drugs in April 2026, bringing the total number of domestically developed medications to 43. That might not sound dramatic until you consider this: for 20 years after the first approval in 1999, South Korea averaged fewer than two new drug approvals annually.

Rimqarto became the 42nd approved drug on April 29th. Developed by Curocell, this personalized cancer treatment extracts a patient's own immune cells, genetically modifies them to fight blood cancer, and returns them to the body. A single dose can treat late-stage blood cancer, and it's the first CAR-T therapy developed entirely in South Korea.

Just one day later, FutureChem's Prostaview Injection earned the 43rd spot. This radioactive pharmaceutical helps doctors pinpoint prostate cancer's exact location and status using PET-CT scans. The timing matters because prostate cancer ranks as the most common cancer among South Korean men.

The acceleration tells a bigger story about South Korean science. From 1989 to 2009, the country managed just 1.4 drug approvals per year on average. Between 2020 and 2025, that number jumped to two per year. Now in 2026, the country has already matched that entire annual average in a single month.

Two factors are driving this momentum. South Korean pharmaceutical and biotech companies have dramatically improved their research capabilities, overcoming earlier limitations in funding, personnel, and clinical trial infrastructure. The government is also doing its part by speeding up the approval process, with new guidelines ensuring reviews wrap up within 295 days.

The Ripple Effect

This breakthrough moment extends far beyond approval numbers. The types of drugs earning approval have evolved from basic antibiotics and blood pressure medications to cutting-edge treatments that were once developed only by global pharmaceutical giants.

Korean companies are now successfully creating CAR-T therapies, radioactive pharmaceuticals, and obesity treatments. These high-difficulty drugs represent some of the most sophisticated medical innovations in the world. KoreaBio noted that this diversity shows South Korean science competing at the highest levels of global drug development.

The race for the 44th approval is already heating up. Hanmi Pharmaceutical's obesity treatment Efpeglenatide applied for approval in December and could launch by mid-2025. Aju Pharmaceutical and GL PharmaTech are awaiting word on Recoflavone, which would become South Korea's first new drug for dry eye syndrome.

Patients worldwide stand to benefit as South Korean innovations reach global markets and inspire faster development cycles elsewhere.